Biosimilar - Global Market Outlook (2016-2022)
According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs has experienced robust market growth. Some of the factors which are triggering the market growth include growing incidences of diseases, rising demand for biosimilars drugs owing to their cost effectiveness and increasing demand to limit healthcare expenditures. However, stringent government regulations will affect biosimilars investments.
Chronic & Autoimmune disorders segment is expected to grow at a highest CAGR during the forecast period owing to increasing incidences of autoimmune disorders. By geography, Europe dominated the global biosimilars market due to growing appearance of new market participants in this region. However, Asia Pacific is anticipated to grow at a highest CAGR during the forecast period due to rising funds towards the expansion of biosimilars market.
Some of the key players in this market include are Mylan, Inc., Dr. Reddy's Laboratories, Amgen Inc., Sandoz International GmbH , Hospira, Inc., Merck KGAA, Celltrion, Inc., Biocon Ltd. , Teva Pharmaceutical Industries Ltd. and Roche Diagnostics.
Products Covered:
Chronic & Autoimmune disorders segment is expected to grow at a highest CAGR during the forecast period owing to increasing incidences of autoimmune disorders. By geography, Europe dominated the global biosimilars market due to growing appearance of new market participants in this region. However, Asia Pacific is anticipated to grow at a highest CAGR during the forecast period due to rising funds towards the expansion of biosimilars market.
Some of the key players in this market include are Mylan, Inc., Dr. Reddy's Laboratories, Amgen Inc., Sandoz International GmbH , Hospira, Inc., Merck KGAA, Celltrion, Inc., Biocon Ltd. , Teva Pharmaceutical Industries Ltd. and Roche Diagnostics.
Products Covered:
- Peptides
- Erythropoietin
- Interferon
- Human Growth Hormone
- Monoclonal Antibodies
- Granulocyte Colony Stimulating Factor (G-CSF)
- Insulin
- Other Products
- Bioassay
- Mass Spectrometry
- Nuclear magnetic resonance (NMR) technology
- Recombinant DNA Technology (rDNA technology)
- Western Blotting
- Electrophoresis
- Chromatography
- Monoclonal Antibodies (MAb) Technology
- Growth Hormone Deficiency
- Chronic and Autoimmune Diseases
- Blood Disorders
- Oncology Diseases
- Other Applications
- Clinical Trials
- Contract Research and Manufacturing Services
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- Rest of Asia Pacific
- Rest of the World
- Middle East
- Brazil
- Argentina
- South Africa
- Egypt
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
1 EXECUTIVE SUMMARY
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 Application Analysis
3.9 Emerging Markets
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL BIOSIMILAR MARKET, BY PRODUCT
5.1 Introduction
5.2 Peptides
5.3 Erythropoietin
5.4 Interferon
5.5 Human Growth Hormone
5.6 Monoclonal Antibodies
5.7 Granulocyte Colony Stimulating Factor (G-CSF)
5.8 Insulin
5.9 Other Products
6 GLOBAL BIOSIMILAR MARKET, BY TECHNOLOGY
6.1 Introduction
6.2 Bioassay
6.3 Mass Spectrometry
6.4 Nuclear magnetic resonance (NMR) technology
6.5 Recombinant DNA Technology (rDNA technology)
6.6 Western Blotting
6.7 Electrophoresis
6.8 Chromatography
6.8.1 Gas Chromatography (GC)
6.8.2 Protein sequencing
6.8.3 Liquid chromatography (LC)
6.9 Monoclonal Antibodies (MAb) Technology
7 GLOBAL BIOSIMILAR MARKET, BY APPLICATION
7.1 Introduction
7.2 Growth Hormone Deficiency
7.3 Chronic and Autoimmune Diseases
7.3.1 Leprosy
7.3.2 Rheumatoid arthritis (RA)
7.3.3 Multiple Sclerosis
7.3.4 Diabetes
7.3.5 Acromegaly
7.3.6 Cystic Fibrosis
7.3.7 Neutropenia
7.4 Blood Disorders
7.4.1 Pulmonary embolism
7.4.2 Hemophilia
7.5 Oncology Diseases
7.5.1 Leukaemia
7.5.2 Colorectal Cancer
7.5.3 Breast Cancer
7.5.4 Prostate Cancer
7.5.5 Cervical Cancer
7.5.6 Lungs Cancer
7.6 Other Applications
8 GLOBAL BIOSIMILAR MARKET, BY SERVICE
8.1 Introduction
8.2 Clinical Trials
8.2.1 Phase I
8.2.2 Phase II
8.2.3 Phase III
8.3 Contract Research and Manufacturing Services
9 GLOBAL BIOSIMILAR MARKET, BY GEOGRAPHY
9.1 North America
9.1.1 US
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 UK
9.2.5 Spain
9.2.6 Rest of Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 Australia
9.3.5 New Zealand
9.3.6 Rest of Asia Pacific
9.4 Rest of the World
9.4.1 Middle East
9.4.2 Brazil
9.4.3 Argentina
9.4.4 South Africa
9.4.5 Egypt
10 KEY DEVELOPMENTS
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 COMPANY PROFILING
11.1 Mylan, Inc.
11.2 Dr. Reddy's Laboratories
11.3 Amgen Inc.
11.4 Sandoz International GmbH
11.5 Hospira, Inc.
11.6 Merck KGAA
11.7 Celltrion, Inc.
11.8 Biocon Ltd.
11.9 Teva Pharmaceutical Industries Ltd.
11.10 Roche Diagnostics
11.11 Biogen idec Inc.
11.12 LG Life Sciences
11.13 Synthon Pharmaceuticals, Inc.
11.14 Novartis AG
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 Application Analysis
3.9 Emerging Markets
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL BIOSIMILAR MARKET, BY PRODUCT
5.1 Introduction
5.2 Peptides
5.3 Erythropoietin
5.4 Interferon
5.5 Human Growth Hormone
5.6 Monoclonal Antibodies
5.7 Granulocyte Colony Stimulating Factor (G-CSF)
5.8 Insulin
5.9 Other Products
6 GLOBAL BIOSIMILAR MARKET, BY TECHNOLOGY
6.1 Introduction
6.2 Bioassay
6.3 Mass Spectrometry
6.4 Nuclear magnetic resonance (NMR) technology
6.5 Recombinant DNA Technology (rDNA technology)
6.6 Western Blotting
6.7 Electrophoresis
6.8 Chromatography
6.8.1 Gas Chromatography (GC)
6.8.2 Protein sequencing
6.8.3 Liquid chromatography (LC)
6.9 Monoclonal Antibodies (MAb) Technology
7 GLOBAL BIOSIMILAR MARKET, BY APPLICATION
7.1 Introduction
7.2 Growth Hormone Deficiency
7.3 Chronic and Autoimmune Diseases
7.3.1 Leprosy
7.3.2 Rheumatoid arthritis (RA)
7.3.3 Multiple Sclerosis
7.3.4 Diabetes
7.3.5 Acromegaly
7.3.6 Cystic Fibrosis
7.3.7 Neutropenia
7.4 Blood Disorders
7.4.1 Pulmonary embolism
7.4.2 Hemophilia
7.5 Oncology Diseases
7.5.1 Leukaemia
7.5.2 Colorectal Cancer
7.5.3 Breast Cancer
7.5.4 Prostate Cancer
7.5.5 Cervical Cancer
7.5.6 Lungs Cancer
7.6 Other Applications
8 GLOBAL BIOSIMILAR MARKET, BY SERVICE
8.1 Introduction
8.2 Clinical Trials
8.2.1 Phase I
8.2.2 Phase II
8.2.3 Phase III
8.3 Contract Research and Manufacturing Services
9 GLOBAL BIOSIMILAR MARKET, BY GEOGRAPHY
9.1 North America
9.1.1 US
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 UK
9.2.5 Spain
9.2.6 Rest of Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 Australia
9.3.5 New Zealand
9.3.6 Rest of Asia Pacific
9.4 Rest of the World
9.4.1 Middle East
9.4.2 Brazil
9.4.3 Argentina
9.4.4 South Africa
9.4.5 Egypt
10 KEY DEVELOPMENTS
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 COMPANY PROFILING
11.1 Mylan, Inc.
11.2 Dr. Reddy's Laboratories
11.3 Amgen Inc.
11.4 Sandoz International GmbH
11.5 Hospira, Inc.
11.6 Merck KGAA
11.7 Celltrion, Inc.
11.8 Biocon Ltd.
11.9 Teva Pharmaceutical Industries Ltd.
11.10 Roche Diagnostics
11.11 Biogen idec Inc.
11.12 LG Life Sciences
11.13 Synthon Pharmaceuticals, Inc.
11.14 Novartis AG
LIST OF TABLES
1 Global Biosimilar Market Outlook, By Region (2013-2022) ($MN)
2 Global Biosimilar Market Outlook, By Product (2013-2022) ($MN)
3 Global Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
4 Global Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
5 Global Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
6 Global Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
7 Global Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
8 Global Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
9 Global Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
10 Global Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
11 Global Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
12 Global Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
13 Global Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
14 Global Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
15 Global Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
16 Global Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
17 Global Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
18 Global Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
19 Global Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
20 Global Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
21 Global Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
22 Global Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
23 Global Biosimilar Market Outlook, By Application (2013-2022) ($MN)
24 Global Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
25 Global Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
26 Global Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
27 Global Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
28 Global Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
29 Global Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
30 Global Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
31 Global Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
32 Global Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
33 Global Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
34 Global Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
35 Global Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
36 Global Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
37 Global Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
38 Global Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
39 Global Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
40 Global Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
41 Global Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
42 Global Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
43 Global Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
44 Global Biosimilar Market Outlook, By Service (2013-2022) ($MN)
45 Global Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
46 Global Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
47 Global Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
48 Global Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
49 Global Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
50 North America Biosimilar Market Outlook, By Country (2013-2022) ($MN)
51 North America Biosimilar Market Outlook, By Product (2013-2022) ($MN)
52 North America Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
53 North America Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
54 North America Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
55 North America Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
56 North America Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
57 North America Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
58 North America Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
59 North America Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
60 North America Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
61 North America Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
62 North America Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
63 North America Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
64 North America Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
65 North America Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
66 North America Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
67 North America Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
68 North America Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
69 North America Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
70 North America Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
71 North America Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
72 North America Biosimilar Market Outlook, By Application (2013-2022) ($MN)
73 North America Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
74 North America Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
75 North America Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
76 North America Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
77 North America Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
78 North America Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
79 North America Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
80 North America Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
81 North America Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
82 North America Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
83 North America Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
84 North America Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
85 North America Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
86 North America Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
87 North America Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
88 North America Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
89 North America Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
90 North America Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
91 North America Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
92 North America Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
93 North America Biosimilar Market Outlook, By Service (2013-2022) ($MN)
94 North America Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
95 North America Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
96 North America Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
97 North America Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
98 North America Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
99 Europe Biosimilar Market Outlook, By Country (2013-2022) ($MN)
100 Europe Biosimilar Market Outlook, By Product (2013-2022) ($MN)
101 Europe Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
102 Europe Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
103 Europe Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
104 Europe Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
105 Europe Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
106 Europe Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
107 Europe Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
108 Europe Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
109 Europe Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
110 Europe Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
111 Europe Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
112 Europe Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
113 Europe Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
114 Europe Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
115 Europe Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
116 Europe Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
117 Europe Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
118 Europe Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
119 Europe Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
120 Europe Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
121 Europe Biosimilar Market Outlook, By Application (2013-2022) ($MN)
122 Europe Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
123 Europe Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
124 Europe Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
125 Europe Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
126 Europe Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
127 Europe Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
128 Europe Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
129 Europe Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
130 Europe Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
131 Europe Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
132 Europe Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
133 Europe Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
134 Europe Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
135 Europe Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
136 Europe Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
137 Europe Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
138 Europe Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
139 Europe Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
140 Europe Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
141 Europe Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
142 Europe Biosimilar Market Outlook, By Service (2013-2022) ($MN)
143 Europe Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
144 Europe Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
145 Europe Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
146 Europe Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
147 Europe Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
148 Asia Pacific Biosimilar Market Outlook, By Country (2013-2022) ($MN)
149 Asia Pacific Biosimilar Market Outlook, By Product (2013-2022) ($MN)
150 Asia Pacific Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
151 Asia Pacific Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
152 Asia Pacific Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
153 Asia Pacific Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
154 Asia Pacific Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
155 Asia Pacific Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
156 Asia Pacific Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
157 Asia Pacific Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
158 Asia Pacific Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
159 Asia Pacific Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
160 Asia Pacific Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
161 Asia Pacific Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
162 Asia Pacific Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
163 Asia Pacific Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
164 Asia Pacific Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
165 Asia Pacific Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
166 Asia Pacific Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
167 Asia Pacific Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
168 Asia Pacific Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
169 Asia Pacific Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
170 Asia Pacific Biosimilar Market Outlook, By Application (2013-2022) ($MN)
171 Asia Pacific Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
172 Asia Pacific Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
173 Asia Pacific Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
174 Asia Pacific Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
175 Asia Pacific Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
176 Asia Pacific Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
177 Asia Pacific Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
178 Asia Pacific Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
179 Asia Pacific Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
180 Asia Pacific Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
181 Asia Pacific Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
182 Asia Pacific Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
183 Asia Pacific Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
184 Asia Pacific Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
185 Asia Pacific Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
186 Asia Pacific Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
187 Asia Pacific Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
188 Asia Pacific Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
189 Asia Pacific Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
190 Asia Pacific Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
191 Asia Pacific Biosimilar Market Outlook, By Service (2013-2022) ($MN)
192 Asia Pacific Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
193 Asia Pacific Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
194 Asia Pacific Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
195 Asia Pacific Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
196 Asia Pacific Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
197 RoW Biosimilar Market Outlook, By Country (2013-2022) ($MN)
198 RoW Biosimilar Market Outlook, By Product (2013-2022) ($MN)
199 RoW Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
200 RoW Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
201 RoW Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
202 RoW Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
203 RoW Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
204 RoW Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
205 RoW Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
206 RoW Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
207 RoW Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
208 RoW Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
209 RoW Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
210 RoW Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
211 RoW Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
212 RoW Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
213 RoW Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
214 RoW Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
215 RoW Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
216 RoW Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
217 RoW Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
218 RoW Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
219 RoW Biosimilar Market Outlook, By Application (2013-2022) ($MN)
220 RoW Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
221 RoW Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
222 RoW Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
223 RoW Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
224 RoW Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
225 RoW Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
226 RoW Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
227 RoW Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
228 RoW Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
229 RoW Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
230 RoW Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
231 RoW Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
232 RoW Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
233 RoW Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
234 RoW Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
235 RoW Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
236 RoW Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
237 RoW Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
238 RoW Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
239 RoW Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
240 RoW Biosimilar Market Outlook, By Service (2013-2022) ($MN)
241 RoW Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
242 RoW Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
243 RoW Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
244 RoW Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
245 RoW Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
1 Global Biosimilar Market Outlook, By Region (2013-2022) ($MN)
2 Global Biosimilar Market Outlook, By Product (2013-2022) ($MN)
3 Global Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
4 Global Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
5 Global Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
6 Global Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
7 Global Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
8 Global Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
9 Global Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
10 Global Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
11 Global Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
12 Global Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
13 Global Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
14 Global Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
15 Global Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
16 Global Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
17 Global Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
18 Global Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
19 Global Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
20 Global Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
21 Global Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
22 Global Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
23 Global Biosimilar Market Outlook, By Application (2013-2022) ($MN)
24 Global Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
25 Global Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
26 Global Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
27 Global Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
28 Global Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
29 Global Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
30 Global Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
31 Global Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
32 Global Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
33 Global Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
34 Global Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
35 Global Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
36 Global Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
37 Global Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
38 Global Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
39 Global Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
40 Global Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
41 Global Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
42 Global Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
43 Global Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
44 Global Biosimilar Market Outlook, By Service (2013-2022) ($MN)
45 Global Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
46 Global Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
47 Global Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
48 Global Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
49 Global Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
50 North America Biosimilar Market Outlook, By Country (2013-2022) ($MN)
51 North America Biosimilar Market Outlook, By Product (2013-2022) ($MN)
52 North America Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
53 North America Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
54 North America Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
55 North America Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
56 North America Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
57 North America Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
58 North America Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
59 North America Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
60 North America Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
61 North America Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
62 North America Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
63 North America Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
64 North America Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
65 North America Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
66 North America Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
67 North America Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
68 North America Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
69 North America Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
70 North America Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
71 North America Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
72 North America Biosimilar Market Outlook, By Application (2013-2022) ($MN)
73 North America Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
74 North America Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
75 North America Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
76 North America Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
77 North America Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
78 North America Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
79 North America Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
80 North America Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
81 North America Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
82 North America Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
83 North America Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
84 North America Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
85 North America Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
86 North America Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
87 North America Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
88 North America Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
89 North America Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
90 North America Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
91 North America Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
92 North America Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
93 North America Biosimilar Market Outlook, By Service (2013-2022) ($MN)
94 North America Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
95 North America Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
96 North America Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
97 North America Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
98 North America Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
99 Europe Biosimilar Market Outlook, By Country (2013-2022) ($MN)
100 Europe Biosimilar Market Outlook, By Product (2013-2022) ($MN)
101 Europe Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
102 Europe Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
103 Europe Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
104 Europe Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
105 Europe Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
106 Europe Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
107 Europe Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
108 Europe Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
109 Europe Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
110 Europe Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
111 Europe Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
112 Europe Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
113 Europe Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
114 Europe Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
115 Europe Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
116 Europe Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
117 Europe Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
118 Europe Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
119 Europe Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
120 Europe Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
121 Europe Biosimilar Market Outlook, By Application (2013-2022) ($MN)
122 Europe Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
123 Europe Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
124 Europe Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
125 Europe Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
126 Europe Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
127 Europe Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
128 Europe Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
129 Europe Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
130 Europe Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
131 Europe Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
132 Europe Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
133 Europe Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
134 Europe Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
135 Europe Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
136 Europe Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
137 Europe Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
138 Europe Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
139 Europe Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
140 Europe Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
141 Europe Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
142 Europe Biosimilar Market Outlook, By Service (2013-2022) ($MN)
143 Europe Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
144 Europe Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
145 Europe Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
146 Europe Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
147 Europe Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
148 Asia Pacific Biosimilar Market Outlook, By Country (2013-2022) ($MN)
149 Asia Pacific Biosimilar Market Outlook, By Product (2013-2022) ($MN)
150 Asia Pacific Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
151 Asia Pacific Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
152 Asia Pacific Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
153 Asia Pacific Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
154 Asia Pacific Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
155 Asia Pacific Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
156 Asia Pacific Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
157 Asia Pacific Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
158 Asia Pacific Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
159 Asia Pacific Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
160 Asia Pacific Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
161 Asia Pacific Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
162 Asia Pacific Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
163 Asia Pacific Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
164 Asia Pacific Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
165 Asia Pacific Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
166 Asia Pacific Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
167 Asia Pacific Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
168 Asia Pacific Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
169 Asia Pacific Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
170 Asia Pacific Biosimilar Market Outlook, By Application (2013-2022) ($MN)
171 Asia Pacific Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
172 Asia Pacific Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
173 Asia Pacific Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
174 Asia Pacific Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
175 Asia Pacific Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
176 Asia Pacific Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
177 Asia Pacific Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
178 Asia Pacific Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
179 Asia Pacific Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
180 Asia Pacific Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
181 Asia Pacific Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
182 Asia Pacific Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
183 Asia Pacific Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
184 Asia Pacific Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
185 Asia Pacific Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
186 Asia Pacific Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
187 Asia Pacific Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
188 Asia Pacific Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
189 Asia Pacific Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
190 Asia Pacific Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
191 Asia Pacific Biosimilar Market Outlook, By Service (2013-2022) ($MN)
192 Asia Pacific Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
193 Asia Pacific Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
194 Asia Pacific Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
195 Asia Pacific Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
196 Asia Pacific Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
197 RoW Biosimilar Market Outlook, By Country (2013-2022) ($MN)
198 RoW Biosimilar Market Outlook, By Product (2013-2022) ($MN)
199 RoW Biosimilar Market Outlook, By Peptides (2013-2022) ($MN)
200 RoW Biosimilar Market Outlook, By Erythropoietin (2013-2022) ($MN)
201 RoW Biosimilar Market Outlook, By Interferon (2013-2022) ($MN)
202 RoW Biosimilar Market Outlook, By Human Growth Hormone (2013-2022) ($MN)
203 RoW Biosimilar Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
204 RoW Biosimilar Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2013-2022) ($MN)
205 RoW Biosimilar Market Outlook, By Insulin (2013-2022) ($MN)
206 RoW Biosimilar Market Outlook, By Other Products (2013-2022) ($MN)
207 RoW Biosimilar Market Outlook, By Technology (2013-2022) ($MN)
208 RoW Biosimilar Market Outlook, By Bioassay (2013-2022) ($MN)
209 RoW Biosimilar Market Outlook, By Mass Spectrometry (2013-2022) ($MN)
210 RoW Biosimilar Market Outlook, By Nuclear magnetic resonance (NMR) technology (2013-2022) ($MN)
211 RoW Biosimilar Market Outlook, By Recombinant DNA Technology (rDNA technology) (2013-2022) ($MN)
212 RoW Biosimilar Market Outlook, By Western Blotting (2013-2022) ($MN)
213 RoW Biosimilar Market Outlook, By Electrophoresis (2013-2022) ($MN)
214 RoW Biosimilar Market Outlook, By Chromatography (2013-2022) ($MN)
215 RoW Biosimilar Market Outlook, By Gas Chromatography (GC) (2013-2022) ($MN)
216 RoW Biosimilar Market Outlook, By Protein sequencing (2013-2022) ($MN)
217 RoW Biosimilar Market Outlook, By Liquid chromatography (LC) (2013-2022) ($MN)
218 RoW Biosimilar Market Outlook, By Monoclonal Antibodies (MAb) Technology (2013-2022) ($MN)
219 RoW Biosimilar Market Outlook, By Application (2013-2022) ($MN)
220 RoW Biosimilar Market Outlook, By Growth Hormone Deficiency (2013-2022) ($MN)
221 RoW Biosimilar Market Outlook, By Chronic and Autoimmune Diseases (2013-2022) ($MN)
222 RoW Biosimilar Market Outlook, By Leprosy (2013-2022) ($MN)
223 RoW Biosimilar Market Outlook, By Rheumatoid arthritis (RA) (2013-2022) ($MN)
224 RoW Biosimilar Market Outlook, By Multiple Sclerosis (2013-2022) ($MN)
225 RoW Biosimilar Market Outlook, By Diabetes (2013-2022) ($MN)
226 RoW Biosimilar Market Outlook, By Acromegaly (2013-2022) ($MN)
227 RoW Biosimilar Market Outlook, By Cystic Fibrosis (2013-2022) ($MN)
228 RoW Biosimilar Market Outlook, By Neutropenia (2013-2022) ($MN)
229 RoW Biosimilar Market Outlook, By Blood Disorders (2013-2022) ($MN)
230 RoW Biosimilar Market Outlook, By Pulmonary embolism (2013-2022) ($MN)
231 RoW Biosimilar Market Outlook, By Hemophilia (2013-2022) ($MN)
232 RoW Biosimilar Market Outlook, By Oncology Diseases (2013-2022) ($MN)
233 RoW Biosimilar Market Outlook, By Leukaemia (2013-2022) ($MN)
234 RoW Biosimilar Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
235 RoW Biosimilar Market Outlook, By Breast Cancer (2013-2022) ($MN)
236 RoW Biosimilar Market Outlook, By Prostate Cancer (2013-2022) ($MN)
237 RoW Biosimilar Market Outlook, By Cervical Cancer (2013-2022) ($MN)
238 RoW Biosimilar Market Outlook, By Lungs Cancer (2013-2022) ($MN)
239 RoW Biosimilar Market Outlook, By Other Applications (2013-2022) ($MN)
240 RoW Biosimilar Market Outlook, By Service (2013-2022) ($MN)
241 RoW Biosimilar Market Outlook, By Clinical Trials (2013-2022) ($MN)
242 RoW Biosimilar Market Outlook, By Phase I (2013-2022) ($MN)
243 RoW Biosimilar Market Outlook, By Phase II (2013-2022) ($MN)
244 RoW Biosimilar Market Outlook, By Phase III (2013-2022) ($MN)
245 RoW Biosimilar Market Outlook, By Contract Research and Manufacturing Services (2013-2022) ($MN)
